Binding of nuclear proteins associated with mammalian DNA repair to the mitomycin C-DNA interstrand crosslink

Environmental and Molecular Mutagenesis

Volumn 31, Issue 1, 1998, Pages 70-81

  Warren, Amy J ^a   Ihnat, Michael A ^b   Ogdon, Sara E ^a   Rowell, Erin E ^a   Hamilton, Joshua W ^a,b,c  

^a Lamont Doherty Earth Observatory   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Cancer chemotherapy; DNA damage; ERCC1; Xeroderma pigmentosum; XPA

Indexed keywords

MITOMYCIN C; NUCLEAR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; GENOTOXICITY; HUMAN; NONHUMAN; PROTEIN BINDING; XERODERMA PIGMENTOSUM;

ANIMALS; CHO CELLS; CRICETINAE; DNA ADDUCTS; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; MITOMYCIN; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEINS; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 0031890163     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1998)31:1<70::AID-EM10>3.0.CO;2-M     Document Type: Article

References (42)

1. Bellon S, Coleman J, Lippard S (1991): DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 30:8026-8035.
2. Bizanek R, McGuinness BF, Nakanishi K, Tomasz M (1992): Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. Biochemistry 31:3084-3091.
3. Borowy-Borowski H, Lipman R, Chowdary D, Tomasz M (1990a): Duplex oligodeoxyribonucleotides cross-linked to mitomycin C at a single site: Synthesis, properties, and cross-link reversibility. Biochemistry 29:2992-2999.
4. Borowy-Borowski H, Lipman R, Tomasz M (1990b): Recognition between mitomycin C and specific DNA sequences for cross-link formation. Biochemistry 29:2999-3006.
5. Bruhn SL, Pil PM, Essigmann JM, Housman DE, Lippard SJ (1992): Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA 89:2307-2311.
6. Caron RM, Hamilton JW (1995a): Preferential effects of the chemotherapeutic DNA crosslinking agent mitomycin C on inducible gene expression in vivo. Environ Mol Mutagen 25:4-11.
7. Caron RM, Hamilton JW (1995b): Developmentally specific effects of mitomycin C on PEPCK gene expression and correlation with chromatin structure. Proc Am Assoc Cancer Res 36:158.
8. Caron RM, Ihnat MA, Hamilton JW (1994): The promoter represents the critical target for the preferential effects of carcinogens on inducible gene expression, and chromatin structure is important for these effects. Proc Am Assoc Cancer Res 35:142.
9. Chao CC-K (1992): Damage-recognition proteins as a potential indicator of DNA-damage-mediated sensitivity of human cells to ultraviolet radiation. Biochem J 282:203-207.
10. Chodos LA (1993): UV crosslinking of proteins to nucleic acids. In Ausubel FM, Brent RE, Kingston DD, Moore DD, Seidman JG, Smith JA, Struhl K (eds): "Current Protocols in Molecular Biology." New York: Greene Publishing Associates and Wiley-Interscience, pp 12.5.1-12.6.9.
11. Dignam JD, Lebovitz RM, Roeder RG (1983): Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
12. Doll CD, Weiss RB, Issell BF (1984): Mitomycin: Ten years after approval for marketing. J Clin Oncol 3:276-286.
13. Ferrari S, Harley VR, Pontiggia A, Goodfellow PN, Lovell-Badge R, Bianchi ME (1992): SRY, like HMG1, recognizes sharp angles in DNA. EMBO J 11:4497-4506.
14. Hamilton JW, Wetterhahn KE (1989): Differential effects of chromium(VI) on constitutive and inducible gene expression in chick embryo liver in vivo and correlation with chromium(VI)-induced DNA damage. Mol Carcinogen 2:274-286.
15. Hamilton JW, Louis CA, Doherty KA, Hunt SR, Reed MJ, Treadwell MD (1993): Preferential alteration of inducible gene expression in vivo by carcinogens that induce bulky DNA lesions. Mol Carcinogen 8:34-43.
16. Hamilton JW, McCaffrey J, Caron RM, Louis CA, Treadwell MD, Hunt SR, Reed MJ, Doherty KA (1994): Genotoxic chemical carcinogens target inducible genes in vivo. Ann NY Acad Sci 726:343-345.
17. Hang B, Yeung AT, Lambert MW (1993): A damage-recognition protein which binds to DNA containing interstrand cross-links is absent or defective in Fanconi's Anemia, complimentation group A, cells. Nucleic Acids Res 21:4187-4192.
18. Hirschfeld S, Levine AS, Ozato K, Protic M (1990): A constitutive damage-specific DNA-binding protein is synthesized at higher levels in UV-irradiated primate cells. Mol Cell Biol 10:2041-2048.
19. Hughes EN, Engclsbcrg BN, Billings PC (1992): Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. J Biol Chem 267:13520-13527.
20. Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JRN, Pierre KM, Turpie BW, Hamilton JW (1997): Suppression of p-glycoprotein expression and multidrug resistance by DNA crosslinking agents. Clin Cancer Res 3:1339-1346.
21. Jones CJ, Wood RD (1993): Preferential binding of the Xerodernia Pigmentosum Group A complementing protein to damaged DNA. Biochemistry 32:12096-12104.
22. Kingston RE (1993): DNA-protein interactions. In Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (eds): "Current Protocols in Molecular Biology." New York: Greene Publishing Associates and Wiley-Interscience pp 12.2.1-12.2.9.
23. Kumar S, Lipman R, Tomasz M (1992): Recognition of specific DNA sequences by mitomycin C for alkylation. Biochemistry 31:1399-1407.
24. Lilley DMJ (1992): DNA-protein interactions: HMG has DNA wrapped up. Nature 357:282-283.
25. McCaffrey J, Hamilton JW (1994): Comparison of effects of directacting DNA methylating and ethylating agents on inducible gene expression in vivo. Environ Mol Mutagen 23:164-170.
26. McCaffrey J, Wolf CM, Hamilton JW (1994): Effects of the genotoxic carcinogen chromium(VI) on basal and hormone-inducible phosphoenolpyruvate carboxykinase gene expression in vivo: Correlation with glucocorticoid-and developmentally-regulated expression. Mol Carcinogen 10:189-198.
27. Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, Tarr PI, Bomsztyk K, Lobb R, Harlan JM, Pohlman TH (1991): Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci USA 88:6523-6527.
28. Norman D, Live D, Sastry M, Lipman R, Hingerty BE, Tomasz M, Broyde S, Patel DJ (1990): NMR and computational characterization of mitomycin cross-linked to adjacent deoxyguanosines in the minor groove of the d(T-A-C-G-T-A) · d(T-A-C-G-T-A) duplex. Biochemistry 29:2861-2875.
29. Pil PM, Lippard SJ (1992): Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256:234-237.
30. Read MA, Whitley MZ, Williams AJ, Collins T (1994): NF-kappa B and I-kappa B alpha: An inducible regulatory system in endothelial activation. J Exp Med 179:503-512.
31. Rice JA, Crothers DM, Pinto AL, Lippard SJ (1988): The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove. Proc Natl Acad Sci USA 85:4158-4161.
32. Rink SM, Lipman R, Alley SC, Hopkins PB, Tomasz M (1996): Bending of DNA by the mitomycin C-induced. GpG intrastrand cross-link. Chem Res Toxicol 9:382-389.
33. Roberts JJ, Thomson AJ (1979): The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol 22:71-133.
34. Svejstrup JQ, Wang Z, Feaver WJ, Wu X, Donohue F, Friedberg EC, Kornberg RD (1995): Different forms of TFIIH for transcription and DNA repair: Holo-TFIIH and a nucleotide excision repairosome. Cell 80:21-28.
35. Tanaka K, Wood RD (1994): Xeroderma Pigmentosum and nucleotide excision repair of DNA. TIBS 19:83-86.
36. Thompson LH, Busch DB, Brookman K, Mooney CL, Glaser D (1981): Genetic diversity of UV-sensitive DNA repair mutants of Chinese hamster ovary cells. Proc Natl Acad Sci USA 78:3734-3737.
37. Tomasz M (1994a): DNA adducts of the mitomycins. In Hemminki K, Dipple A, Shuker DEG, Kadlubar FF, Segerback D, Bartsch H (eds): "DNA Adducts: Identification and Biological Significance." Lyon: IARC, pp 349-357.
38. Tomasz M (1994b): The mitomycins: natural cross-linkers of DNA. In Neidle S, Waring M (eds): "Molecular Aspects of Anticancer Drug-DNA Interactions. Volume 2." Boca Raton FL: CRC Press, pp 313-349.
39. 3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: Effects of hypoxia and dicumerol on adduct patterns. Cancer Commun 3:213-223.
40. Toney JH, Donahue BA, Kellett PJ, Bruhn SL, Essigmann JM, Lippard SJ (1989): Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II). Proc Natl Acad Sci USA 86:8328-8332.
41. 2G interstrand crosslink in a model synthetic 23 base pair oligonucleotide DNA duplex. Chem Res Toxicol 9:1063-1071.
42. Wood RD (1995): Proteins that participate in nucleotide excision repair of DNA in mammalian cells. Phil Trans R Soc Lond B 347:69-74.